DE60313743D1 - Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen - Google Patents

Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen

Info

Publication number
DE60313743D1
DE60313743D1 DE60313743T DE60313743T DE60313743D1 DE 60313743 D1 DE60313743 D1 DE 60313743D1 DE 60313743 T DE60313743 T DE 60313743T DE 60313743 T DE60313743 T DE 60313743T DE 60313743 D1 DE60313743 D1 DE 60313743D1
Authority
DE
Germany
Prior art keywords
influenza
protein
pseudotypized
hemagglutinine
influenzavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313743T
Other languages
English (en)
Other versions
DE60313743T2 (de
Inventor
John Cristian Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
University of North Carolina at Chapel Hill
University of North Carolina System
Original Assignee
Oxford Biomedica UK Ltd
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd, University of North Carolina at Chapel Hill, University of North Carolina System filed Critical Oxford Biomedica UK Ltd
Publication of DE60313743D1 publication Critical patent/DE60313743D1/de
Application granted granted Critical
Publication of DE60313743T2 publication Critical patent/DE60313743T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Vending Machines For Individual Products (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
DE60313743T 2002-02-04 2003-02-04 Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen Expired - Lifetime DE60313743T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0202569.0A GB0202569D0 (en) 2002-02-04 2002-02-04 Delivery means
GB0202569 2002-02-04
PCT/GB2003/000496 WO2003066868A1 (en) 2002-02-04 2003-02-04 Retroviral vectors pseudotyped with influenza virus hemagglutinin for gene delivery

Publications (2)

Publication Number Publication Date
DE60313743D1 true DE60313743D1 (de) 2007-06-21
DE60313743T2 DE60313743T2 (de) 2008-01-24

Family

ID=9930369

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313743T Expired - Lifetime DE60313743T2 (de) 2002-02-04 2003-02-04 Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen

Country Status (7)

Country Link
US (1) US7659113B2 (de)
EP (2) EP1813676B1 (de)
AT (1) ATE361989T1 (de)
AU (1) AU2003244404A1 (de)
DE (1) DE60313743T2 (de)
GB (1) GB0202569D0 (de)
WO (1) WO2003066868A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2430991T3 (es) 2000-06-01 2013-11-22 Dnavec Research Inc. Vector retroviral seudotipo que contiene proteína de membrana que tiene actividad hemaglutinina
CA2830887C (en) 2001-06-05 2016-11-29 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
AU2003261931A1 (en) * 2002-09-04 2004-03-29 Dnavec Research Inc. Process for producing virus vector containing membrane protein having sialic acid-binding activitiy in envelope with the use of gram-positive bacterium-origin neuraminidase
EP2993235B1 (de) 2005-10-28 2019-02-13 ID Pharma Co., Ltd. Gentransfer in epithelialen stammzellen der atemwege unter verwendung von similian lentiviralen vektoren mit senadai rna-virus-spikeprotein pseudotypisierten vektoren
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
CN101888854A (zh) * 2006-12-29 2010-11-17 上海巴斯德研究所 用流感病毒血凝素假型包装的慢病毒和使用方法
WO2009036063A1 (en) * 2007-09-11 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudotyped retroviral vectors and methods of making and using them
US9206440B2 (en) 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
ES2430991T3 (es) * 2000-06-01 2013-11-22 Dnavec Research Inc. Vector retroviral seudotipo que contiene proteína de membrana que tiene actividad hemaglutinina

Also Published As

Publication number Publication date
EP1478759B1 (de) 2007-05-09
EP1813676A3 (de) 2007-09-26
DE60313743T2 (de) 2008-01-24
US20050123515A1 (en) 2005-06-09
EP1478759A1 (de) 2004-11-24
WO2003066868A1 (en) 2003-08-14
EP1813676B1 (de) 2012-07-25
US7659113B2 (en) 2010-02-09
EP1813676A2 (de) 2007-08-01
GB0202569D0 (en) 2002-03-20
ATE361989T1 (de) 2007-06-15
AU2003244404A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
ATE435297T1 (de) Retrovirales verabreichungssystem
DK1129190T3 (da) Human TSLP DNA og polypeptider
DE60235761D1 (de) Isoform des vegfs
DE69941059D1 (de) Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden
DK1601776T3 (da) Ekspressionsvektorer omfattende mCmV-IE2-promotoren
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
NO20043419L (no) Nytt cytokin, zcytor17-ligand
ATE496134T1 (de) Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
DE60313743D1 (de) Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen
ATE328073T1 (de) Ehrlichia canis protein
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
ATE420157T1 (de) Zielgerichtete genveraenderung mit parvoviralen vektoren
ATE504654T1 (de) Promotoren zur expression in modifiziertem vaccinia virus ankara
DE50214936D1 (de) Verwendung des adenoviralen e2-late-promotors
HUP0001857A2 (hu) Bakteriális plazmidok
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
DE60229966D1 (de) Diabetesmodell
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE59914061D1 (de) Das gen prv-1 und dessen verwendung
DK1317548T3 (da) Transglutaminasegenprodukter
ATE311459T1 (de) Die ltr-region von msrv-1 und die durch sie kodierten proteine, und sonden und methoden für detektion des msrv-1 retrovirus
DE60330140D1 (de) Gen-silencing-vektor und diesen verwendendes gen-silencing-verfahren
EP1568775A4 (de) Krebs-assoziiertes gen
ATE517181T1 (de) Rekombinante carboxypeptidase b
ATE506439T1 (de) Codon-optimisierte hiv-rt-nef-gag dna impfstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition